TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure

• Main Authors: Jin Lei (Author), Bowen Chen (Author), Meiru Song (Author), Linzhi Zhang (Author), Xinfeng Zhang (Author), Xiaoqiang Gao (Author), Yinyin Li (Author), Yinying Lu (Author), Shi Zuo (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Tyrosine kinase inhibitors (TKI) in combination with programmed cell death-1 (PD-1) inhibitors become the potential treatment modality for patients undergoing unresectable hepatocellular carcinoma (uHCC) in the first-line setting. However, the efficacy and safety of this combination regi...